Theratechnologies reports positive Phase III results

Canada-based Theratechnologies has unveiled positive Phase III results evaluating the long-term safety profile of tesamorelin (TH9507), in patients with HIV-associated lipodystrophy. The long-term results are consistent with the safety profile observed in the first 26 weeks of treatment and show that tesamorelin is well tolerated.

"Our objective was to demonstrate long-term safety, and we have clearly achieved this. In addition, we continue to differentiate tesamorelin from other compounds being evaluated in HIV-associated lipodystrophy as having a favorable risk/benefit profile for patients," commented Mr. Yves Rosconi, President and CEO of Theratechnologies.

- check out Theratechnologies' release for more

Suggested Articles

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.

AbbVie is tapping a triumvirate of life science groups to develop a new antibody for the COVID-19 virus.